Abstract
Several neurological diseases such as bipolar disorders and schizophrenia are linked to impaired brain energy metabolism. A key feature of brain bioenergetics is hexokinase (HK) binding to the outer mitochondrial membrane through the voltage dependent anion channel (VDAC). This has metabolic consequences, with phosphorylation of glucose by mitochondrially bound hexokinase being closely coupled to production of substrate ATP by intramitochondrial oxidative phosphorylation. Additionally, binding of HK to mitochondria inhibits Bax-induced cytochrome c release and apoptosis. Moreover VDAC1 expression level is elevated in cerebellum of patients with Down ´s syndrome, while in Alzheimer ´s disease, VDAC1 levels are decreased in frontal cortex and VDAC2 elevated in temporal cortex. Thus, understanding the roles of VDAC and HK, either separate or interacting in brain, provides new opportunities and challenges to elucidate pathophysiological mechanisms for future therapeutic strategies.
Keywords: Energy metabolism, glycolysis, hexokinase, lactate, neurons, VDAC.
Current Molecular Pharmacology
Title:Role of Hexokinase and VDAC in Neurological Disorders
Volume: 9
Author(s): José César Rosa and Marcelo de Cerqueira César
Affiliation:
Keywords: Energy metabolism, glycolysis, hexokinase, lactate, neurons, VDAC.
Abstract: Several neurological diseases such as bipolar disorders and schizophrenia are linked to impaired brain energy metabolism. A key feature of brain bioenergetics is hexokinase (HK) binding to the outer mitochondrial membrane through the voltage dependent anion channel (VDAC). This has metabolic consequences, with phosphorylation of glucose by mitochondrially bound hexokinase being closely coupled to production of substrate ATP by intramitochondrial oxidative phosphorylation. Additionally, binding of HK to mitochondria inhibits Bax-induced cytochrome c release and apoptosis. Moreover VDAC1 expression level is elevated in cerebellum of patients with Down ´s syndrome, while in Alzheimer ´s disease, VDAC1 levels are decreased in frontal cortex and VDAC2 elevated in temporal cortex. Thus, understanding the roles of VDAC and HK, either separate or interacting in brain, provides new opportunities and challenges to elucidate pathophysiological mechanisms for future therapeutic strategies.
Export Options
About this article
Cite this article as:
Rosa César José and César de Cerqueira Marcelo, Role of Hexokinase and VDAC in Neurological Disorders, Current Molecular Pharmacology 2016; 9 (4) . https://dx.doi.org/10.2174/1874467209666160112123036
DOI https://dx.doi.org/10.2174/1874467209666160112123036 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Letters in Drug Design & Discovery JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy Heat Shock Response Regulates Insulin Sensitivity and Glucose Homeostasis: Pathophysiological Impact and Therapeutic Potential
Current Diabetes Reviews Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics Advances in Current Diabetes Proteomics: From the Perspectives of Label- free Quantification and Biomarker Selection
Current Drug Targets Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Current Neuropharmacology RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Retracted: Zebrafish Caspase-3: Molecular Cloning, Characterization, Crystallization and Phylogenetic Analysis
Protein & Peptide Letters Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience